Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

POLB 001

Next Previous
Drug Profile

POLB 001

Alternative Names: HVO-001; POLB-001; UR-13870; UR-138780

Latest Information Update: 20 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Uriach
  • Developer Centre for Human Drug Research; Palau Pharma; Poolbeg Pharma
  • Class Anti-inflammatories; Antivirals; Fluorobenzenes; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Influenza virus infections

Highest Development Phases

  • Phase I Cytokine release syndrome; Influenza virus infections
  • Discontinued Autoimmune disorders; Inflammation

Most Recent Events

  • 07 Dec 2024 Pharmacodynamics data from a preclinical study in Cytokine release syndrome presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 20 Mar 2024 Poolbeg Pharma receives patent allowance for POLB 001(Immunomodulator II) in USA
  • 09 Dec 2023 Adverse events and pharmacodynamics data from a phase-I trial in Influenza virus infections presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023) (NCT05765955)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top